Biopharmaceutical Manufacturing, Upstream, Downstream …
2025年1月16日 · News on the biopharmaceutical manufacturing industry, focusing on biologics, technology, upstream/downstream processing, cell culture and regulations
News - biopharma-reporter.com
2025年1月14日 · News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Nanobiotix’s radiotherapy-activated nanoparticle cancer candidate ...
1 天前 · The French biotech company Nanobiotix announced today that it has dosed the first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating its …
‘Biotech remains the biopharma industry’s engine of innovation …
2022年6月28日 · While COVID-19 dominated biotech innovation and revenues in 2021, the wider industry enjoyed increased activity as well. Excluding emergency use authorizations for …
How will the Biosecure Act impact the pharma industry?
2024年10月8日 · But what does the Act mean for the biotech and pharma industry and how can companies best prepare for any impacts on future business? The Biosecure Act was first …
Umoja raises $100 million to boost its CAR-T cell gene therapy …
2025年1月16日 · The oversubscribed Series C financing round will support the clinical development of in vivo CAR-T cells for oncology and autoimmune diseases. The U.S. biotech …
Biosimilars in the UK: Insights from Biocon Biologics
2 天之前 · Josh Gissing is Cluster Head (UK, Ireland & Nordics) for Biocon Biologics: a biosimilars company whose business model seeks to make biologic therapies affordable, accessible and …
Trends in biosimilars: Regulatory approvals in 2024
2024年7月24日 · The biosimilars market is rapidly growing as global demand for biosimilars continues to grow. The global biosimilar market is estimated to reach a size of $43.8 billion by …
Cell and gene therapy will be top industry trend for pharma in 2024
2024年1月8日 · Healthcare industry professionals scored cell and gene therapy (CGT) as the industry trend to have the greatest impact on the pharmaceutical industry in 2024, in a recent …
EMA accepts Marketing Authorization Application for biosimilar to …
2024年11月5日 · The European Medicines Agency (EMA) has accepted Alvotech and Advanz Pharma’s marketing authorization application for AVT05, a biosimilar to Johnson & Johnson’s …